[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579942":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":146,"collaborators":20,"id":148,"slug":149,"hasResults":150,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":20,"eligibilityCriteria":154,"healthyVolunteers":150,"sex":155,"minAge":156,"maxAge":20,"enrollmentInfo":157,"targetDuration":20,"studyType":160,"phases":161,"briefSummary":163,"conditions":164,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},{"fullName":5,"class":6},"Atridia Pty Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},": HRS-5041 dose level 1","EXPERIMENTAL","240 mg BID",[13],"Drug: HRS-5041 Single dose of HRS-5041 orally administered",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","HRS-5041 Single dose of HRS-5041 orally administered","HRS-5041 Oral dosage (Tablet) Oral dosage administration, 28 days per cycle.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Kathy You","CONTACT","+61 02 9299 0433","kathyyou@atridia.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Ravi Patel","+61 452 363 506","ravi.patel@atridia.com",[32,49,57,70,77,88,96,107,118,126,135],{"facility":33,"status":34,"city":35,"state":36,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"GenesisCare North Shore (Oncology)","RECRUITING","Sydney","New South Wales","Australia","AU",{"type":40,"coordinates":41},"Point",[42,43],151.20732,-33.86785,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":20,"phoneExt":20,"email":20},"Ganessan Kichenadasse","PRINCIPAL_INVESTIGATOR",{"facility":50,"status":34,"city":35,"state":36,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"Sydney Adventist Hospital",{"type":40,"coordinates":52},[42,43],{"lat":43,"lon":42},[55],{"name":56,"role":48,"phone":20,"phoneExt":20,"email":20},"Gavin Marx, Prof",{"facility":58,"status":34,"city":59,"state":60,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Cancer Research SA","Adelaide","South Australia",{"type":40,"coordinates":62},[63,64],138.59863,-34.92866,{"lat":64,"lon":63},[67,69],{"name":68,"role":24,"phone":20,"phoneExt":20,"email":20},"Sarwan Bishnoi",{"name":68,"role":48,"phone":20,"phoneExt":20,"email":20},{"facility":71,"status":34,"city":59,"state":60,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":72,"geoPoint":74,"contacts":75},"Southern Oncology Clinical Research Unit",{"type":40,"coordinates":73},[63,64],{"lat":64,"lon":63},[76],{"name":47,"role":48,"phone":20,"phoneExt":20,"email":20},{"facility":78,"status":34,"city":79,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Icon Cancer Centre South Brisbane","Brisbane",{"type":40,"coordinates":81},[82,83],153.02809,-27.46794,{"lat":83,"lon":82},[86],{"name":87,"role":48,"phone":20,"phoneExt":20,"email":20},"Jermaine Coward, Dr",{"facility":89,"status":34,"city":79,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"John Flynn Private Hospital",{"type":40,"coordinates":91},[82,83],{"lat":83,"lon":82},[94],{"name":95,"role":48,"phone":20,"phoneExt":20,"email":20},"David Martin, Dr",{"facility":97,"status":34,"city":98,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Eastern Health (Box Hill Hospital)","Melbourne",{"type":40,"coordinates":100},[101,102],144.96332,-37.814,{"lat":102,"lon":101},[105],{"name":106,"role":48,"phone":20,"phoneExt":20,"email":20},"Ian Davis",{"facility":108,"status":34,"city":109,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Linear Clinical Research Ltd","Perth",{"type":40,"coordinates":111},[112,113],115.8614,-31.95224,{"lat":113,"lon":112},[116],{"name":117,"role":48,"phone":20,"phoneExt":20,"email":20},"Timothy Humphries, Dr",{"facility":119,"status":34,"city":35,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":120,"geoPoint":122,"contacts":123},"Macquarie University",{"type":40,"coordinates":121},[42,43],{"lat":43,"lon":42},[124],{"name":125,"role":48,"phone":20,"phoneExt":20,"email":20},"Howard Gurney",{"facility":127,"status":34,"city":35,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":128,"geoPoint":130,"contacts":131},"MUPharm Pty Limited trading as Macquarie University Hospital Pharmacy",{"type":40,"coordinates":129},[42,43],{"lat":43,"lon":42},[132,134],{"name":133,"role":24,"phone":20,"phoneExt":20,"email":20},"Jane Stidworthy",{"name":125,"role":48,"phone":20,"phoneExt":20,"email":20},{"facility":136,"status":34,"city":137,"state":20,"zip":20,"country":37,"countryCode":38,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Illawarra Shoalhaven Local Health District (Wollongong Hospital)","Wollongong",{"type":40,"coordinates":139},[140,141],150.89345,-34.424,{"lat":141,"lon":140},[144],{"name":145,"role":48,"phone":20,"phoneExt":20,"email":20},"Gary Tincknell, Dr",{"type":147,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100579942","phase-1-a-trial-of-hrs-5041-103-to-evaluate-the-safety-tolerability-pharmacokinetics-and-efficacy-of-hrs-5041-in-subjects-with-metastatic-castration-resistant-prostate-cancer-100579942",false,"NCT06830850","A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer","A Phase I, Open-label, Multi-Center, Non-Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer","IInclusion Criteria\n\n1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.\n2. Adequate bone marrow and other vital organ functions\n3. Adequate liver function tests\n4. Metastatic Castration-resistant Prostate Cancer\n\nExclusion Criteria\n\n1. Plan to receive any other anti-tumor therapy during the study.\n2. Receipt of any chemotherapy, targeted therapy, immunotherapy, live\u002Fattenuated vaccination, radiotherapy or surgery within 4 weeks prior to the first dosing of this study.\n3. Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\> 150 mmHg and\u002For diastolic blood pressure \\[DBP\\] \\> 100 mmHg with regular anti-hypertension therapy).\n4. Factors that may affect the oral administration of the IP (swallow difficulty, chronic diarrhea, and bowel obstruction, etc.), or active gastrointestinal (GI) disease or other disease which may affect the absorption, distribution, metabolism, or elimination of IP.\n5. Known history of drug allergies, specific allergies (such as asthma, urticaria, eczema, etc.).\n6. Active heart disease within 6 months prior to the first dosing of this study.\n7. Medical history of other malignant tumor within 5 years prior to dosing.\n8. Positive hepatitis B virus (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C virus (HCV-Ab), or syphilis or severe infections which need treatment.","MALE","18 Years",{"count":158,"type":159},25,"ESTIMATED","INTERVENTIONAL",[162],"PHASE1","To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.",[165],"Metastatic Castration Resistant Prostate Cancer","2026-01-13",{"date":168,"type":169},"2026-01-15","ACTUAL",{"date":171,"type":169},"2025-06-15",{"date":173,"type":159},"2027-03-15",{"name":5,"class":6},11]